Annovera Ring
Product Images NDC 68308-752

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Annovera (NDC 68308-752). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Annovera 01)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years in different groups: Non-CHC users, non-pregnant (range 1 to 5); CHC users (range 3 to 12); pregnant women (range 5 to 20); and postpartum women at 12 weeks only (range 40 to 65).*

FDA Label Image

Figure 2 (Annovera 02)

A forest plot showing effect estimates with confidence intervals for various studies comparing Ever COC vs. Never COC use and Current COC vs. Never Use. The horizontal axis represents the effect estimate scale from -1.50 to 2.00. Study names and years are listed on the left, with odds ratios (OR), relative risks (RR), and hazard ratios (HR) on the right.*

FDA Label Image

Chemical Structure (Annovera 03)

Chemical structure of segesterone acetate, one of the active ingredients in Annovera vaginal ring. The diagram shows the molecular arrangement including characteristic steroid rings and functional groups.*

FDA Label Image

Chemical Structure (Annovera 04)

Chemical structure diagram of the active ingredient ethinyl estradiol showing its molecular framework with hydroxyl groups and other functional groups labeled by carbon numbers.*

FDA Label Image

Figure 3 (Annovera 05)

Two line graphs showing the concentration levels of ethinyl estradiol (EE) and segesterone acetate in pg/mL over time in hours after insertion of the Annovera vaginal ring. The graphs display data for cycles 1, 3, and 13, depicting changes in hormone levels across these cycles up to approximately 672 hours.*

FDA Label Image

Figure 4 (Annovera 06)

Two line graphs showing concentrations of hormones over 48 hours after insertion of Annovera vaginal ring. The left graph displays segesterone acetate levels (pg/mL) and the right graph shows ethinyl estradiol (EE) levels (pg/mL). Both graphs depict hormone levels across different usage cycles (1, 3, 13) with time (hours) on the x-axis.*

FDA Label Image

Figure (Annovera 07)

An illustration diagram showing a vertical arrow labeled 'Fewer Pregnancies' at the top and 'More Pregnancies' at the bottom. To the left are pregnancy rates per 100 women per year, ranging from fewer than 1 to 85 or more. To the right are boxed lists of birth control methods categorized by effectiveness: highest effectiveness includes implants, injections, intrauterine devices, and sterilization; next includes birth control pills, skin patch, vaginal rings with hormones, and vaginal systems with hormones; followed by condoms and diaphragms; then methods like no sex during fertile days, spermicide, and withdrawal; and finally, no birth control with the highest pregnancy rate.*

FDA Label Image

Figure (Annovera 08)

Illustration showing a hand holding a vaginal ring as the first step in product use. The hand grips the ring between thumb and forefinger, demonstrating how to hold the Annovera contraceptive vaginal ring prior to insertion.*

FDA Label Image

Figure (Annovera 09)

An instructional line drawing showing a hand holding a vaginal ring. The image depicts Step 2 of the insertion process, demonstrating how to fold or position the Annovera vaginal ring before insertion.*

FDA Label Image

Figure (Annovera 10)

Illustration showing three different body positions for vaginal ring insertion labeled as Step 3-A, 3-B, and 3-C. The positions include lying down with knees bent, squatting, and standing with one foot elevated on a surface. The diagrams depict a person demonstrating methods to facilitate ring placement.*

FDA Label Image

Figure (Annovera 11)

An anatomical diagram showing the female pelvic region with labeled parts: uterus, bladder, urethra, cervix, vagina, rectum, and anus. The diagram is part of an instructional figure, labeled STEP 4-A, likely illustrating placement related to the vaginal ring dosage form.*

FDA Label Image

Figure (Annovera 12)

An anatomical diagram showing a sagittal view of female pelvic organs with labels identifying the uterus, bladder, urethra, cervix, vagina, rectum, and anus. The image is labeled as STEP 4-B, likely illustrating vaginal ring placement.*

FDA Label Image

Figure (Annovera 13)

Diagram illustrating female pelvic anatomy with labeled parts including uterus, bladder, urethra, cervix, vagina, rectum, and anus, marked as Step 5 in a sequence.*

FDA Label Image

Principal Display Panel (30 Ring Pouch Carton)

The packaging label for Annovera vaginal system contains segesterone acetate and ethinyl estradiol. The label shows the product delivering 0.15 mg and 0.013 mg per day respectively. It includes directions for vaginal use, a statement on prevention of pregnancy, and cautions about HIV and STD protection. The label is primarily blue and white with text in blue and black, features the Mayne Pharma logo, and states the package contains 1 vaginal system. The NDC 68308-752-01 is visible along with barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.